Cash Flow Statement (Annual)

LJPC / La Jolla Pharmaceutical Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities
  Net Income Loss -3,760 -11,548 -7,737 -17,935 -21,313 -41,912 -78,185 -114,803
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Share Based Compensation 489 254 8,604 12,373 8,992 11,551 14,349 20,776
    Depreciation - 0 0 5 17 347 730 1,268
    Gain Loss On Disposition Of Assets1 - - - 0 0 -16 -75 -199
    Increase Decrease In Operating Capital
      Increase Decrease In Inventories And Other Operating Assets - - - - - - - -
      Increase Decrease In Prepaid Deferred Expense And Other Assets -519 -7 -35 18 94 -824 664 1,642
      Increase Decrease In Other Operating Assets - - - 0 0 70 149 -219
      Increase Decrease In Accounts Payable And Accrued Liabilities -231 31 -49 822 -104 2,322 3,600 4,832
      Increase Decrease In Accrued Liabilities And Other Operating Liabilities - - - 80 739 -248 227 -202
      Increase Decrease In Employee Related Liabilities -88 -78 10 56 324 666 987 2,918
      Increase Decrease In Deferred Rent - - - - - 0 124 335
  Net Cash Provided By Used In Operating Activities -3,391 -1,826 -2,135 -4,734 -12,879 -25,183 -58,672 -84,881
Net Cash Provided By Used In Investing Activities
  Payments To Acquire Property Plant And Equipment - - 0 43 258 1,816 2,218 9,194
  Net Cash Provided By Used In Investing Activities - - 0 -43 -258 -1,816 -2,218 -9,194
Net Cash Provided By Used In Financing Activities
  Proceeds From Issuance Of Common Stock - - 0 6,751 53,063 104,596 0 117,480
  Proceeds From Stock Options Exercised - 0 0 0 0 315 149 2,693
  Net Cash Provided By Used In Financing Activities 6,003 - 500 10,001 53,063 104,911 149 119,264
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - -
Cash Cash Equivalents And Short Term Investments
  Cash And Cash Equivalents At Carrying Value - 5,040 3,405 8,629 48,555 126,467 65,726 90,915
  Restricted Cash Current - - - - - - - -
  Restricted Cash Noncurrent - - - - - - - -

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 503459604